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Background: Complement 5a receptor (C5aR) was demonstrated a receptor of complement 5a (C5a) which is
involved in many inflammatory diseases. The functional responses attributed to C5a results from its interaction with
its receptors C5aR, which stimulates food intake, plays a role in increasing the inflammatory response in adipose
tissue as well as the cardiovascular and neural systems. However, There are unknown associations between the
SNPs of C5aR1 gene and coronary artery disease (CAD).
Methods: We examined the role of the tagging single nucleotide polymorphisms (SNPs) of C5aR1 gene for CAD
using a case–control design, and determined the prevalence of C5aR1 genotypes in 505 CAD patients and 469 age
and sex-matched healthy control subjects of Han population.
Results: The rs10853784 was found to be associated with CAD in dominant model (CC vs TT + CT, P = 0.004). The
difference remained statistically significant after multivariate adjustment (OR = 1.430, 95% CI: 1.087 ~ 1.882, P = 0.011).
There was no significant difference in genotype distributions of rs4577202 and rs7250152 between CAD patients and
control subjects. The frequency of the haplotype (A-T-C) was significantly higher in the CAD patients than in the
controls (P = 0.035), and the haplotype (A-C-T) was significantly lower in the CAD patients than in the control subjects
in Chinese Han population (P = 0.002).
Conclusion: The results of this study indicate that rs10853784 of C5aR1 gene are associated with CAD in Han
population of China, and A-C-T haplotypes may be protective genetic marker and the A-T-C may be risk genetic marker
for CAD in Chinese Han population.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
2054871241495194.
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The role of the immune system and inflammatory path-
ways in the development of atherosclerotic disease is
well established [1]. Recent evidences claimed that in-
flammation might represent the pathophysiological link
between obesity and metabolic syndrome (MetS) [2].
Since adipose tissue is now considered an endocrine* Correspondence: myt_xj@sina.com
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unless otherwise stated.organ, affecting metabolism and vascular function. The
understanding of these pathways is crucial from a patho-
physiological point of coronary artery disease (CAD) risk
stratification and to the identification of possible thera-
peutic targets. Disorders of lipoprotein metabolism such
as elevated levels of triglyceride (TG), Lipoprotein (a)
[Lp(a)] as well as increased fasting blood glucose are
considered to be important risk factors in the patho-
genesis of atherosclerosis and CAD [3-6]. CAD is a
chronic inflammatory disease. There is evidence on the
role of inflammation in all stages of the atherosclerotic
disease process [7,8]. Genetic studies have revealed manyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CAD [9,10].
C5a is a multifunctional protein, which promotes the
recruitment and activation of neutrophils and monocytes
[3]. Pathological conditions such as sepsis and various
immunoinflammatory disorders are accompanied by in-
creases in circulating C5a [11-13]. C5a interacts prima-
rily with its two receptors, the classic proinflammatory
C5a receptor (C5aR; CD88) and relative newly identified
C5a receptore like 2 (C5L2). C5aR is a member of the
rhodopsin family of G protein-coupled receptors (GPCR)
which is expressed at varying levels in different im-
mune and non-immune cells [14-17]. A recent research
demonstrated that the C5aR Knockout(KO) mice have
decreased fat mass, glucose clearance and insulin tole-
rance [18]. The C5a-C5aR pathway has been targeted for
pharmacological therapy for treatment of sepsis, cardio-
vascular diseases, and autoimmune disorders [19,20].
C5L2, which resembles C5aR (58% homology) [12] was
demonstrated to be a functional receptor of acylation-
stimulating protein (ASP), increased transport of glucose
and esterification of fatty acids, leading to a net accumu-
lation of TG stores influence the body’s susceptibility to
CAD [21-23].
In previous studies [24-26], we identified C5L2 gene
which is associated with CAD and T2DM in Chinese
Han and Uygur population. The activity of C5L2 may in-
fluence the individual’s susceptibility to CAD. Accor-
dingly, we screened for tagging SNPs of the C5aR1 gene
and assessed the association between the genotypes of
this gene and CAD in Chinese Han population.
Methods
Ethical approval of the study protocol
Written informed consent was obtained from all partici-
pants. An approval of ethics committee by the Ethics
Committee of the First Affiliated Hospital of Xinjiang
Medical University (Xinjiang, China) was obtained. It
was conducted in accordance with the guidelines of the
Helsinki Declaration.
Subjects
Participants diagnosed with CAD were recruited at the
First Teaching Hospital of Xinjiang Medical University
from 2007 to 2010. The detailed diagnostic and selection
criteria have been previously described [27,28]. Briefly,
CAD was defined as the presence of at least one signifi-
cant coronary artery stenosis of ≥50% luminal diameter
on coronary angiography. Patients were excluded if they
had congenital hypercoagulable status with proven
disease-limiting life expectancy or had abused cocaine.
The healthy participants were selected from the cardio-
vascular risk survey (CRS). The CRS has been described
previously [29]. This study consists of 14,618 subjectsand is a multiple-ethnic, community-based, cross-sectional
study designed to investigate the prevalence, incidence, and
risk factors for cardiovascular diseases in the Han, Uygur,
and Kazakh population in Xinjiang (west China) between
June 2007 and March 2010. These control individuals did
not have a history of CAD, electrocardiographic signs of
CAD, regional wall motion abnormalities, and relevant
valvular abnormalities in echocardiograms [30].
In this study, 505 patients with CAD and 469 healthy
control participants were enrolled. All study participants
were Han Chinese ethnicity and were from the same geo-
graphic area in Xinjiang. Demographic data and subject
characteristics, including hypertension, diabetes mellitus,
smoking, alcohol consumption, and serum cholesterol,
were collected for all study participants. Diabetes, hyper-
tension, hyperlipidemia, smoking, and alcohol consump-
tion were defined as described previously [27-29].
Biochemical analysis
Serum concentrations of total cholesterol (TC), TG,
glucose, high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), apolipopro-
tein B (Apo B), LP (a) were measured using standard
methods in the Central Laboratory of First Affiliated
Hospital of Xinjiang Medical University as described pre-
viously [27-29].
Sample DNA extraction
Blood samples were collected from all participants using a
standard venipuncture technique and EDTA-containing
tubes. DNA was extracted from the peripheral blood
leukocytes using a whole blood genome extraction kit
(Beijing Bioteke Corporation, Beijing, China. (http://bioteke.
technew.cn) as previously described [27,29].
Genotyping of C5aR1 gene
The genotyping for the C5aR1 gene was performed by using
ABI 7900 Real Time PCR System (Applied Biosystems).
Amplification was performed in 6ul of volume, including
1ul of DNA, 3ul of Master Mix, 0.05ul of Probe(40X),
MiliQ add to 6ul. Real time PCR was performed according
to the protocol as follows: After an initial holding step of
Pre-heated 95°C for 10 min, samples were cycled 20 times
at 95°C for 10s, at 65°C-55°C for 15 s (Each loop drops by
0.5°C), at 60°C for15s. Then the samples were cycled 25
times at 95°C for 10s, at 60°C for 30s, pre/post read
(Starting from 60°C at 0.06°C/s was slowly warmed to
61°C, and collecting the fluorescence value). Cooling (cool
at 40°C to maintain).
Statistical analyses
Statistical analysis was performed using the SPSS version
17.0 software (SPSS, Chicago, IL, USA), Data are
expressed as the mean ± standard deviation (SD). The
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continuous variables and the χ2 test for non-continuous
variables. The differences between CAD patients and con-
trol subjects were assessed by independent-sample t-test.
Categorical variables were analyzed as frequencies. Allele
and genotype frequencies among CAD cases and controls
were compared with values predicted by using the Chi-
square test. Hardy-Weinberg equilibrium was assessed by
chi-square analysis. Multivariate analysis was performed
using a logistic regression analysis for independent variables
that were related to the presence or absence of CAD. A
value of P < 0.05 was considered significant.
Results
Characteristics of participants
Table 1 shows demographic and clinical characteristics
of 974 study subjects. CAD patients (n = 505) and
healthy control subjects (n = 469), the following variables
were significantly different between the two groups: dia-
betes and drinking; the serum concentration of glucose,
apo B and LP(a) (all P < 0.05). There was no significant
difference in the following variables between CAD pa-
tients and control subjects: hypertation; smoking, the
body mass index (BMI); serum concentration of TG,
HDL, and LDL, age, and sex (all P > 0.05).
Distribution of the SNPs for C5aR1 gene in CAD patients
and controls
Table 2 shows distribution of genotypes and alleles of
SNPs for C5aR1 gene. The genotypes distributions for
each of the SNPs were in good agreement with theTable 1 Characteristics of the participants
Characteristics CAD (n = 505)
Age, mean (SD) 61.91 (9.94)
Sex, female (%) 169 (33.46)
Hypertension, n (%) 239 (47.33)
Diabetes, n (%) 105 (20.79)
Smoking, n (%) 47 (9.30)
Drinking, n (%) 27 (5.34)
BMI, mean (SD) 25.50 (3.277)
Apo B, mean (SD) 1.02 (2.87)
Lipoprotein(a), mean (SD) 203.53 (190.51)
TG, mean (SD) 2.87 (13.71)
TC, mean (SD) 4.27 (1.15)
HDL-C, mean (SD) 1.53 (7.77)
LDL-C, mean (SD) 3.69 (13.09)
Glucose, mean (SD) 6.25 (2.60)
Note: Continuous variables are expressed as mean ± SD. Categorical variables are ex
cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprot
Independent t-test. The P value of the categorical variables was calculated by Fishepredicted Hardy-Weinberg equilibrium values (data not
shown). There was no significant difference between CAD
and control subjects for rs4577201 (SNP1) and rs7250152
(SNP2) (all P > 0.05). Distribution of rs10853784 (SNP3)
genotypes, dominant model (CC vs TT + CT), additive
model (CT vs CC + TT) and allele frequency showed sig-
nificant difference between CAD and control subjects
(P = 0.016, P = 0.004, P = 0.021 and P = 0.004, respectively).
There was no significant difference between CAD and
control subjects for recessive model (TT vs CC+CT,
P = 0.191).
Table 3 shows multivariable logistic regression analysis
combining genotypes with following variables: plasma
concentration of lipoprotein(a), incidence of diabetes,
drinking and smoking which were the major confoun-
ding factors for CAD. After multivariate adjustment,
rs10853784 remain significantly associated with CAD in
dominant model (CC vs CT + TT) (OR = 1.430, 95% con-
fidence interval [CI]:1.087 ~ 1.882, P = 0.011).
Haplotypes of the C5aR1 Gene Associated with CAD
In the haplotype-based case–control analysis, haplotypes
were established through the use of different combina-
tions of the SNPs (Table 4). The overall distribution of
the haplotypes established by SNP1-SNP2-SNP3 was
significantly different between the CAD patients and the
control subjects. The frequency of the A-C-T haplotype
established by SNP1-SNP2-SNP3 in these two groups
was also significantly lower for the CAD patients as
compared to the control subjects (OR = 0.714, 95% CI =
0.577-0.883, P = 0.002). Moreover, the frequency of theControl (n = 469) χ2 or t P value
57.31 (10.27) 1.631 0.202
159 (33.90) 0.019 0.47
208 (44.35) 0.868 0.368
39 (8.31) 30.045 <0.001
47 (10.02) 0.142 0.745
42 (8.96) 4.811 0.033
25.90 (3.40) 0.896 0.344
0.84 (0.23) 4.033 0.045
170.42 (149.69) 17.673 <0.001
1.94 (1.54) 3.46 0.06
4.35 (1.03) 2.907 0.089
1.13 (0.35) 3.716 0.054
3.20 (13.64) 0.999 0.318
5.56 (1.77) 35.393 <0.001
pressed as percentages. BMI, body mass index; TG, triglyceride; TC, total
ein cholesterol; The P value of the continuous variables was calculated by the
r’s exact test.
Table 2 Genotype and allele distributions in patients with CAD and control participants
rs4577202(SNP1) rs7250152(SNP2) rs10853784(SNP3)
Variant CAD n(freq) Control n(freq) P value Variant CAD n(freq) Control n(freq) P value Variant CAD n(freq) Control n(freq) P value
Genotype Genotype Genotype
AA 325(0.644) 309(0.658) 0.814 TT 166(0.328) 132(0.282) 0.277 TT 20(0.040) 27(0.058) 0.016
AG 156(0.309) 141(0.301) CT 237(0.470) 234(0.499) CT 151(0.299) 173(0.369)
GG 24(0.047) 19(0.041) CC 102(0.202) 103(0.219) CC 334(0.661) 269(0.574)
Dominant model Dominant model Dominant model
AA 325(0.644) 309(0.658) 0.617 TT 166(0.328) 132(0.282) 0.110 CC 334(0.661) 269(0.574) 0.004
AG + GG 180(0.356) 160(0.342) CT + CC 339(0.672) 337(0.719) CT + TT 170(0.339) 200(0.426)
Recessive model Recessive model Recessive model
GG 24(0.047) 19(0.041) 0.575 CC 102(0.202) 103(0.219) 0.500 TT 20(0.040) 27(0.058) 0.191
AA + AG 481(0.953) 454(0.959) CT + TT 403(0.798) 366(0.781) CT + CC 485(0.960) 442(0.942)
Additive model Additive model Additive model 0.021
AG 156(0.309) 141(0.301) 0.779 CT 237(0.470) 234(0.499) 0.335 CT 151(0.299) 173(0.369)
AA + GG 349(0.691) 328(0.699) CC + TT 268(0.530) 235(0.501) CC + TT 354(0.701) 296(0.631)
Allele Allele Allele
A 806(0.799) 759(0.809) 0.536 T 569(0.563) 498(0.532) 0.150 T 191(0.193) 227(0.241) 0.004
G 204(0.201) 179(0.191) C 441(0.437) 440(0.468) C 819(0.807) 711(0.759)











Table 3 Multiple logistic regression analysis for CAD patients and control subjects
B S.E. χ2 P OR 95% CI
Dominant model (CC vs CT + TT) (SNP3) .358 .140 6.537 .011 1.430 1.087 ~ 1.882
Diabetes 1.059 .210 25.442 <0.001 2.885 1.911 ~ 4.354
Smoking .617 .333 3.442 .064 1.854 0.966 ~ 3.559
Drinking −1.053 .388 7.356 .007 .349 0.163 ~ 0.747
Lipoprotein(a) .001 .000 6.068 .001 .229 1.000 ~ 1.002
Constant −1.473 .438 11.328 .001 .248
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these two groups was also significantly higher for the CAD
patients compared to the control subjects (OR = 1.213,
95% CI = 1.014-1.452, P = 0.035).
Discussion
Factors such as diabetes, hypertension, inflammation
and hyperlipidemia have been reported to influence the
pathogenesis of CAD. Like hyperlipemia and diabetes,
CAD is thought to be a multifactorial disease. Hence,
much attention has been focused on the association of
gene polymorphisms with CAD.
The C5aR and C5L2, was identified in 1991 [31,32]
and 2000 [33], respectively. Both genes are localized to
the same region of chromosome 19, q13.33 and encoded
in a two exon structure, with the 5′-untranslated region
and initiating codon in the first exon, and the remainder
of the coding sequence and the 3′-untranslatedregion in
the second [34]. This is typical of the members of the
chemoattractant receptor family. In the promoter region of
C5aR, an SNP at position-245 (T/C) has been discovered
[35] and the coding region. C5aR has two non-synonymous
SNPs at 4G/A (Asp/Asn at amino-acid position 2) and
859G/T (Asn/Lys at position 278) and two synonymous
SNPs: 72 T/C and 727G/A [36]. To date, no SNPs have
been identified in the coding region of the C5aR1 gene as-
sociation with human disease. C5aR, which binds C5a, is
involved in many inflammatory diseases [37]. One previous
study showed that C5a stimulates food intake [38], the
C5aR KO mice demonstrated decreased body weight and
fat storage [22]. Studies earlier showed the higher levels of
C5a was associated with late lumen loss of drug-eluting
stents [39,40]. Early atherosclerotic lesions express C5aR,
which may indicate that inflammatory cells are initially
recruited into the damaged vessels through C5aR [41].Table 4 Haplotype analysis in patients with CAD and control
Haplotype SNP1 SNP2 SNP2 Case(freq)
H1 A C C 243.50(0.229)
H2 A C T 192.89(0.182)
H3 A T C 412.31(0.388)
H4 G T C 183.38(0.173)Other research reported that C5a concentration was more
elevated in hypertensive individuals than in healthy people.
C5aR signaling pathway on blood monocytes/macrophages
plays a pathological role in angiotensin II (Ang II)-induced
cardiac inflammation and remodeling. Complement pro-
teins such as complement C3 [42,43], C5L2 [44,45] and
C3aR [46] have all been implicated in lipid and glucose me-
tabolism. C5L2 is similar to C5aR in structure, C5L2
was associated with hyperlipidemia and diabetes, and
the C5L2 genetic variant was associated with CAD
and this association is not modified by the concentra-
tion of TG and glucose.
In our study, we found that polymorphisms of C5aR1
were associated with CAD in a Han population. There
was significant difference in genotype distribution of
rs10853784 between CAD patients and control subjects.
For the rs10853784 genotypes, dominant model (CC vs
TT + CT), additive model (CT vs CC +TT) and allele fre-
quency showed significant difference between CAD and
control subjects. After multivariate adjustment of con-
founding factors the significant difference was retained.
For genes with multiple susceptibilities, an analysis
based on haplotypes has advantages over an analysis
based on individual SNPs, particularly when the linkage
disequilibria between the SNPs is weak [47]. Our study
is the first haplotype-based case–control study to inves-
tigate the association between the human C5aR1 gene
and CAD in the Chinese Han population. In our study,
we succeeded in identifying two haplotypes (A-C-T and
A-T-C) of SNP1-SNP2-SNP3 in Chinese Han population.
Based on the haplotype and logistic regression analyses,
we believe that the haplotype (A-C-T) is a protective fac-
tor for CAD (OR = 0.714, P = 0.002), and A-T-C is an risk
factor for CAD (OR = 1.213, P = 0.035) in Chinese Han
population.subjects
Control(freq) χ2 P value Odds ratio [95% CI]
221.08(0.218) 0.671 0.413 1.090 [0.886 ~ 1.342]
244.07(0.241) 9.701 0.002 0.714 [0.577 ~ 0.883]
354.84(0.351) 4.441 0.035 1.213 [1.014 ~ 1.452]
181.83(0.180) 0.05 0.823 0.974 [0.777 ~ 1.222]
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In conclusion, this is the first time that correlations bet-
ween the human C5aR1 gene and CAD have been
examined in the Chinese population. The present data
indicate that C5aR1gene is associated with CAD in Han
population of China. This result may broaden the know-
ledge of genetic variants and disease-association studies.
Study limitation
The present study was limited by the relatively small
sample size. This may have led to weak statistical signifi-
cance and wide CIs when estimating ORs.
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